Highlights

  • Ten % came out first: 558,119,895 shares were released at the close of trading on 27 August 2025, following an ASX release lodged on 20 August 2025 under Listing Rule 3.10A.
  • Sigma lodged the notice for that second release on 9 July 2026.
  • The announcement carried statements of intent rather than binding commitments.
  • The half-year to 31 December 2025, reported on 26 February 2026, is the most recent audited-period picture.

Sigma Healthcare will report its FY26 full-year results on 27 August 2026, with an investor briefing scheduled for 10am AEST. On the same day, at the close of ASX trading, 5,023,079,098 fully paid ordinary shares held by the Chemist Warehouse founders come out of voluntary Escrow .

The stock traded around AUD 2.97 intraday on 11 August 2026, little changed, for a Market Capitalisation near AUD 34.2 billion.

Company Overview

Sigma is now the listed vehicle for one of the largest pharmacy retail and wholesale operations in the country, combining a pharmaceutical wholesale and distribution network with retail brands including Chemist Warehouse, My Chemist, Amcal and Discount Drug Stores, plus international Chemist Warehouse stores.

Recent Developments

The escrow arrangement is the detail worth pinning down. At Merger implementation, three Shareholder groups gave voluntary escrow undertakings: Mario Verrocchi and associated entities over 2,555,284,920 shares, Jack Gance and associated entities over 1,579,050,058, and Sam Gance and associated entities over 1,446,864,015 — 5,581,198,993 shares in total.

The structure was two-stage. Ten % came out first: 558,119,895 shares were released at the close of trading on 27 August 2025, following an ASX release lodged on 20 August 2025 under Listing Rule 3.10A.

Financial Snapshot

The half-year to 31 December 2025, reported on 26 February 2026, is the most recent audited-period picture. Revenue was AUD 5.5 billion, up 14.9 %. Normalised EBIT was AUD 582.9 million, up 18.7 %, and normalised NPAT was AUD 392.0 million, up 19.2 %.

Operating Cash Flow was AUD 317.4 million and free cash flow AUD 284.6 million. Net Debt sat at AUD 635.1 million, or 0.6 times normalised EBITDA. The Interim Dividend was 2.0 cents per share, about 60 % of normalised Earnings , which on roughly 11.5 billion shares on issue amounts to some AUD 230 million in cash.

What to Watch

The 27 August briefing should bring the FY26 result, a final dividend decision, an updated synergy tally against the AUD 100 million FY29 target and store rollout numbers. Any Block Trade or substantial holder notice in the days after the release would be the next concrete signal on founder intentions.

Risks

Concentration is the defining risk: three shareholder groups control a very large slice of the register and are represented on the board. Synergy delivery is back-ended and unproven at scale. GLP-1 Demand has been a visible sales driver and is exposed to pricing, Supply and reimbursement change.

Outlook

Sigma goes into 27 August with momentum in the numbers and an unusual overhang in the register. If the result confirms the first-half trajectory and synergies are tracking, attention will move to how the founders behave once the restriction lifts.